Mr. Karavetsos will step down Jan. 20 — the same day President-elect Donald Trump will be sworn in as president.
While an FDA spokeswoman confirmed the departure, she declined to share any additional information or say whether the two events are related.
Mr. Karavetsos has served as head of the OCI since January 2015. The office conducts criminal investigations into allegations surrounding food, drugs, medical devices, cosmetics and tobacco.
More articles on supply chain:
FDA approves Allergan’s breast implant
Red Cross issues emergency call for blood donations amid winter shortage
Descartes Systems acquires logistics trade data provider for $52.7M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.